HIMABERB® supports healthy blood glucose and cholesterol levels
Berberine is a natural plant compound found in various plants, including Berberis aristata. It has been widely studied for its potential health benefits, such as improving blood sugar control, reducing inflammation, and promoting weight loss.
Berberis aristata extract taken at a 97% concentration of berberine hydrochloride (HIMABERB®) is considered the most effective berberine supplement for several reasons. 
Firstly, it contains a high concentration of berberine, which is the active compound responsible for its health benefits. This high concentration means that a smaller dose can be taken, which may reduce the risk of potential side effects.
Secondly, Berberis aristata extract has been shown to have superior bioavailability compared to other sources of berberine. Bioavailability refers to the amount of a substance that is absorbed into the bloodstream and available for the body to use. Studies have shown that the absorption of berberine from Berberis aristata extract is significantly higher than that from other sources, such as goldenseal or barberry.
HIMABERB® is studied to support blood glucose and cholesterol parameters in 2 double blind, randomized, placebo controlled human trials.
- The study aimed to assess the impact of daily oral berberine (HIMABERB®) on glycemic control in prediabetic individuals. A 12-week randomized, double-blinded, placebo-controlled trial with 34 participants showed significant reductions in fasting blood glucose, insulin resistance, 2-hour glucose tolerance, and HbA1c in the berberine-treated group compared to the placebo. Berberine was well-tolerated with no severe adverse effects, indicating its potential as an intervention to delay progression to diabetes mellitus. The study supports the exploration of HIMABERB® for managing prediabetes.
- In a 12-week double-blind, placebo-controlled trial, the efficacy of HIMABERB® (water-extracted berberine hydrochloride) on blood lipid markers in prediabetic individuals was investigated. Thirty-four participants received HIMABERB® or a placebo. HIMABERB® demonstrated a significant reduction in total cholesterol, low-density lipoprotein (LDL), and triglycerides, along with an improvement in high-density lipoprotein (HDL) compared to baseline and the control group. No serious adverse effects were reported, suggesting HIMABERB® is well-tolerated. The study suggests that an 84-day intervention with HIMABERB® significantly affects lipid markers in prediabetic individuals, indicating its potential as an adjunct in managing blood lipid parameters in this population.
References:
- Panigrahi, A. and Mohanty, S. (2023) Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: Double-blind, placebo-controlled, and randomized pilot trial - BMC endocrine disorders, BioMed Central. Available at: https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-023-01442-y (Accessed: 04 January 2024).